- Residency - UT Southwestern Medical Center (1999-2003), Urology
- Residency - UT Southwestern Medical Center (1998-1999), General Surgery
- Internship - UT Southwestern Medical Center (1997-1998), General Surgery
- Medical School - Baylor College of Medicine (1993-1997)
Yair Lotan, M.D.
- Helen J. and Robert S. Strauss Professorship in Urology
- Genitourinary Cancer
- Kidney Cancer
Yair Lotan, M.D., is a Professor of Urology, Chief of Urologic Oncology, and holder of the Helen J. and Robert S. Strauss Professorship in Urology at UT Southwestern Medical Center. He is also the Medical Director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System.
He was class valedictorian in high school and graduated with high honors from the University of Texas at Austin and Baylor College of Medicine in Houston. He trained in general surgery and urology at UT Southwestern and joined the faculty in 2003.
A board-certified urologist, Dr. Lotan treats patients with bladder, prostate, kidney, ureteral, and testicular cancer. He also handles general urologic conditions, such as kidney stones and vasectomies.
He is known nationally for his research on urine markers and molecular markers, which will help determine which patients are at higher risk for recurrent cancer. He is also involved in health economics research, which evaluates the cost-effectiveness of surgery and cancer prevention. Dr. Lotan is the co-chair of the Harold C. Simmons Comprehensive Cancer Center disease oriented team for urologic cancers. He is also a member of UT Southwestern’s Clinical Research Planning Group and the Tissue Bank Steering Committee and Cancer Committee.
He is a frequent guest speaker at medical conferences around the world and belongs to numerous professional organizations, including the American Urological Association, the Society of Urologic Oncology, and the Bladder Cancer Advocacy Network.
He has published hundreds of research articles and several book chapters on urologic care and procedures, and he serves as editorial reviewer for medical periodicals such as the Journal of Urology, European Urology, Cancer, Urologic Oncology, and the British Journal of Urology International.
Dr. Lotan was included in D Magazine's Best Doctors list for 2018.
Meet Dr. Lotan
Yair Lotan, M.D., was born to be a physician: His parents are retired cancer researchers from MD Anderson Cancer Center in Houston, and both of his brothers are also doctors.
“With my parents both being scientists, I couldn’t help but be interested in science, too,” he says.
A board-certified urologist at UT Southwestern Medical Center, Dr.
Lotan uses minimally invasive, robotic, and open surgical techniques to
treat bladder, prostate, kidney, ureteral, and testicular cancer. He was
the first in North Texas to perform a robotic cystectomy, or removal of
the bladder. He also treats kidney stones endoscopically and
"We routinely treat patients with advanced urologic cancers, rather than just seeing one or two per year."
Professor of Urology, Chief of Urologic Oncology, and holder of the Helen J. and Robert S. Strauss Professorship in Urology at UT Southwestern, Dr. Lotan is also Medical Director of the Urology Clinic at Parkland Health & Hospital System. He is nationally recognized for his research on urine markers in bladder cancer and molecular markers in other urologic cancers.
“Molecular markers help us identify patients who are at a higher risk for recurrent cancer so we can recommend the appropriate treatment for them,” he says. “And on the flip side, if their cancer is unlikely to recur, we can try to reduce the number of treatments so they don’t have as many side effects.”
Dr. Lotan enjoys getting to know his patients and educating them so they can make informed decisions about their urologic care and procedures.
“Cancer impacts all aspects of your life and it is important to consider not only how to treat the cancer but also how to minimize side effects and improve quality of life,” he says. “Patients also want to be educated and involved in their decisions so they can get the best possible outcomes.”
- Society of Urologic Oncology/Society of Endourology
- R.O.C.K. Society
- National Urologic Ultrasound Faculty
- American Urologic Association
- American Association for Cancer Research
- The Pfizer Scholars in Urology Award 2002, Urology Pathology Course
- Gerald P. Murphy Scholar Award 2003, Recognition of Research in Prostate Cancer
- Who’s Who in America 2008
- Best Poster 2008, Society of Urologic Oncology Annual Meeting on Extraordinary Opportunities for Discovery National Cancer Institute
- Merit Award 2009, American Society of Clinical Oncology (ASCO) Cancer Foundation at the Genitourinary Cancers Symposium
Lymphovascular Invasion is Independently Associated with Overall Survival, Cause-Specific Survival, and Locan and Distant Recurrence in Patients with Negative Lymph Nodes at Radical Cystectomy
Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AIJ Clin Oncol. August 2005 August 22
Role of biomarkers to predict outcomes and response to therapy
Lotan YUrol Oncol January 2010 28(1) 97-101
Prospective Evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial cardinoma of the bladder
Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq RJ Urol June 2008 179(6) 2164-9
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes
Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SMJ Clin Oncol. March 2005 20;23(9) 1911-20
The influence of body mass index on the cost of radical prostatectomy for prostate cancer
Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG, Lotan YBJU Int March 2010 23
Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker
Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI,J Urol May 2009
Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers
Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C. Sagalowsky AI, Ashfaq R, Lotan YJ Urol May 2010 183(5) 1744-50
BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress
Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan YUrol Oncol May 2010 28(3): 334-7 334-7
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study
Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Muller SC, Sagalowsky AI, Lotan YClin Cancer Res November 2009 15(22) 7012-19
Survivin as a prognostic marker for urothelial carcinoma of the bladdre: a multicenter external validation study
Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C. Bastian PJ, Nielsen ME, Muller SC, Sagalowsky AI, Lotan YClin Cancer Res November 2010 15(22) 7012-19
- Lymphovascular Invasion is Independently Associated with Overall Survival, Cause-Specific Survival, and Locan and Distant Recurrence in Patients with Negative Lymph Nodes at Radical Cystectomy
- Urologic oncology
- Robotic and laparoscopic surgery
- Decision analysis and outcomes research
- Biomarker research
- Genitourinary Cancer
- Kidney Cancer
- Testicular Cancer
- General Urology
- Genitourinary Surgery
- Surgical Treatment of Genitourinary Cancer
- Bladder Cancer
- Prostate Cancer
- Male Urology